LungenClinic Grosshansdorf
11
5
6
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.
Role: collaborator
HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort
Role: collaborator
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Role: collaborator
COPD Exacerbation Modelling Using Unobtrusive Sensors - the TOLIFE Clinical Study A
Role: collaborator
Adult Arm of DZL All Age Asthma Cohort (ALLIANCE)
Role: lead
HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections
Role: lead
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Role: collaborator
Hyperspectral Imaging in Thoracic Surgery
Role: lead
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
Role: collaborator
Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles (FNA-22G-25G)
Role: collaborator
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Role: lead
All 11 trials loaded